Current and historical daily PE Ratio for NRX Pharmaceuticals Inc (
STU:B1Q
) from 2020 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. NRX Pharmaceuticals stock (STU:B1Q) PE ratio as of Jun 21 2024 is 0.
More Details
NRX Pharmaceuticals Inc (STU:B1Q) PE Ratio (TTM) Chart
NRX Pharmaceuticals Inc (STU:B1Q) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 745
- 1
- 2
- 3
- 4
- 5
- 6
- 9
NRX Pharmaceuticals PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-21 | At Loss | 2024-01-31 | At Loss |
2024-04-03 | At Loss | 2024-01-30 | At Loss |
2024-04-02 | At Loss | 2024-01-29 | At Loss |
2024-03-29 | At Loss | 2024-01-26 | At Loss |
2024-03-28 | At Loss | 2024-01-25 | At Loss |
2024-03-27 | At Loss | 2024-01-24 | At Loss |
2024-03-26 | At Loss | 2024-01-23 | At Loss |
2024-03-25 | At Loss | 2024-01-22 | At Loss |
2024-03-22 | At Loss | 2024-01-19 | At Loss |
2024-03-21 | At Loss | 2024-01-18 | At Loss |
2024-03-20 | At Loss | 2024-01-17 | At Loss |
2024-03-19 | At Loss | 2024-01-16 | At Loss |
2024-03-18 | At Loss | 2024-01-15 | At Loss |
2024-03-15 | At Loss | 2024-01-12 | At Loss |
2024-03-14 | At Loss | 2024-01-11 | At Loss |
2024-03-13 | At Loss | 2024-01-10 | At Loss |
2024-03-12 | At Loss | 2024-01-09 | At Loss |
2024-03-11 | At Loss | 2024-01-08 | At Loss |
2024-03-08 | At Loss | 2024-01-05 | At Loss |
2024-03-07 | At Loss | 2024-01-04 | At Loss |
2024-03-06 | At Loss | 2024-01-03 | At Loss |
2024-03-05 | At Loss | 2024-01-02 | At Loss |
2024-03-04 | At Loss | 2024-01-01 | At Loss |
2024-03-01 | At Loss | 2023-12-29 | At Loss |
2024-02-29 | At Loss | 2023-12-28 | At Loss |
2024-02-28 | At Loss | 2023-12-27 | At Loss |
2024-02-27 | At Loss | 2023-12-26 | At Loss |
2024-02-26 | At Loss | 2023-12-25 | At Loss |
2024-02-23 | At Loss | 2023-12-22 | At Loss |
2024-02-22 | At Loss | 2023-12-21 | At Loss |
2024-02-21 | At Loss | 2023-12-20 | At Loss |
2024-02-20 | At Loss | 2023-12-19 | At Loss |
2024-02-19 | At Loss | 2023-12-18 | At Loss |
2024-02-16 | At Loss | 2023-12-15 | At Loss |
2024-02-15 | At Loss | 2023-12-14 | At Loss |
2024-02-14 | At Loss | 2023-12-13 | At Loss |
2024-02-13 | At Loss | 2023-12-12 | At Loss |
2024-02-12 | At Loss | 2023-12-11 | At Loss |
2024-02-09 | At Loss | 2023-12-08 | At Loss |
2024-02-08 | At Loss | 2023-12-07 | At Loss |
2024-02-07 | At Loss | 2023-12-06 | At Loss |
2024-02-06 | At Loss | 2023-12-05 | At Loss |
2024-02-05 | At Loss | 2023-12-04 | At Loss |
2024-02-02 | At Loss | 2023-12-01 | At Loss |
2024-02-01 | At Loss | 2023-11-30 | At Loss |
NRX Pharmaceuticals Inc (STU:B1Q) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
NRX Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US6294441000
Share Class Description:
STU:B1Q: Ordinary SharesDescription
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.